Kevin Duffy
Physician Assistant · Lansing, MINPI 1164412565
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 1,430 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by Johnson & Johnson at 25.0% of the total. Among physician assistant clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,430 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$6K
- Amgen$4K
- UCB, Inc.$3K
- AbbVie$3K
- AstraZeneca$1K
- Novartis$1K
- plus $6K from 32 others
What the payments were for
- Food & beverage$22,10696%
- Education$8814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 498 | $5,751 |
| Amgen(2 entities) | 215 | $3,722 |
| UCB, Inc. | 126 | $2,994 |
| AbbVie | 192 | $2,670 |
| AstraZeneca(2 entities) | 67 | $1,321 |
| Novartis | 54 | $1,020 |
| Mallinckrodt Hospital Products Inc. | 44 | $977 |
| ANI Pharmaceuticals, Inc. | 30 | $552 |
| E.r. Squibb & Sons, L.L.C. | 30 | $530 |
| Pfizer | 29 | $428 |
| Boehringer Ingelheim | 19 | $397 |
| Lilly USA, LLC | 21 | $382 |
| Organon | 16 | $287 |
| Janssen Scientific Affairs, LLC | 3 | $283 |
| Sobi, Inc | 12 | $235 |
| Sandoz | 9 | $197 |
| Radius Health, Inc. | 9 | $171 |
| Fresenius Kabi USA, LLC | 7 | $163 |
| Genentech USA, Inc. | 7 | $121 |
| Sanofi | 6 | $114 |
| Aurinia Pharma U.S., Inc. | 5 | $94 |
| Alvogen Inc | 5 | $88 |
| Kyowa Kirin, Inc. | 4 | $80 |
| Actelion Pharmaceuticals US, Inc. | 3 | $66 |
| Merck | 2 | $49 |
| Bioventus LLC | 3 | $42 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Fidia Pharma USA Inc. | 2 | $34 |
| United Therapeutics Corporation | 1 | $32 |
| Boston Scientific | 1 | $25 |
| Tersera Therapeutics LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Arcutis Biotherapeutics, Inc. | 1 | $17 |
| Hospira, Inc. | 1 | $14 |
| Invivyd Inc | 1 | $14 |
| Mylan Institutional Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $13 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$112
How this compares
$22,987 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 72 | $445,181 |
| Humira(Cf) PenAdalimumab | 40 | $312,249 |
| EnbrelEtanercept | 39 | $284,858 |
| Orencia ClickjectAbatacept | 42 | $240,493 |
| Enbrel SureclickEtanercept | 30 | $224,497 |
| SimponiGolimumab | 16 | $160,057 |
| Humira(Cf)Adalimumab | 18 | $152,047 |
| Xeljanz XrTofacitinib Citrate | 23 | $147,959 |
| BenlystaBelimumab | 29 | $136,022 |
| OtezlaApremilast | 19 | $116,939 |
| Actemra ActpenTocilizumab | 24 | $111,827 |
| Hydroxychloroquine Sulfate | 647 | $53,879 |
| MethotrexateMethotrexate Sodium | 447 | $19,232 |
| Leflunomide | 180 | $14,489 |
| Mycophenolate Mofetil | 63 | $9,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $2,670 | $597,22890 claims |
| AmgenEnbrel, Otezla | $3,722 | $401,79658 claims |
| Johnson & JohnsonSimponi | $5,751 | $160,05716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Lansing
- Lauren KaylorLansing$23K
- Antonio GiannelliLansing$22K
- Timothy PalmerLansing$17K
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.